Bio

Adam Evertts is a Director of Research who re-joined LifeSci Capital in 2018 to help launch the Alpha Series research product. He recently spent 2 years as an Associate at Sofinnova Partners, a venture capital firm based in Paris, where he conducted deep diligence on early-stage biotechnology companies. At Sofinnova he contributed to 3 investments and was a Board Observer for a seed investment in the CNS space. Adam spent 3 years at LifeSci prior to the introduction of the Alpha Series and helped implement several expert-driven research activities such as physician surveys and KOL dinners at medical meetings. Adam received his PhD from Princeton University where he studied the dynamics of histone modifications during cell division and upon cell cycle arrest. Prior to graduate school he spent two years at a Postbaccalaureate Fellow at the National Institutes of Health. Adam holds the Series 7, 24, 86 and 87.